An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Ferring Pharmaceuticals
- 16 Oct 2017 Planned End Date changed from 1 Jan 2019 to 1 May 2019.
- 16 Oct 2017 Planned primary completion date changed from 1 Jan 2019 to 1 May 2019.
- 10 Jun 2017 Biomarkers information updated